EUVIMEDEUVIMED entdecken
Crossref

Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma

Nian Liu, Zehui Qi, Wenqiang Sun, Minghui Tong, Xuan Shi, Han Wang, Shuyi Mu, Ningyuan Hu, Zirui Luo, Cunzheng Fan, Haoyu Zhang, Zixuan Gao und 3 weitere

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19065-19087

DOI: 10.1021/acs.jmedchem.6c01348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.07.2026. Verfasst von Nian Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical Uni…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Quinazolines, Neuroblastoma, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: 3D BioOptima (Suzhou), Program for Innovative Research Team of the Ministry of Education, Program for Liaoning Innovative Research Team in University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polo-like kinase 4 (PLK4), a master regulator of centrosome duplication, has emerged as an attractive therapeutic target in oncology. Notably, the synthetic lethality between PLK4 inhibition and TRIM37 amplification provides a strong rationale for targeted tumor intervention. However, the limited structural diversity of current PLK4 inhibitors constrains further development. Herein, structure-guided scaffold-hopping and fragment growth strategies were employed to develop a series of structurally novel quinazoline-based PLK4 inhibitors. The optimized compound B33 (ZSL-M028) exhibited potent PLK4 inhibition (IC50 = 1.1 nM), excellent selectivity over Aurora A kinase (over 1600-fold), and favorable ADME and pharmacokinetic properties, including an oral bioavailability of 55.4%. M028 further demonstrated significant in vitro and in vivo antitumor activity against TRIM37-amplified neuroblastoma with a favorable safety profile. Overall, M028 represents a promising lead for PLK4 inhibition, and offers new opportunities for precision therapy in TRIM37-amplified neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesQuinazolinesNeuroblastomaUbiquitin-Protein LigasesAntineoplastic AgentsProtein Kinase InhibitorsTripartite Motif ProteinsHumansAnimalsAdministration, OralStructure-Activity RelationshipCell Line, TumorMiceDrug Screening Assays, AntitumorDrug DiscoveryNuclear Proteins

Stichwörter der Autor:innen

NeuroblastomaPolo-like kinase 4Quinazoline-derivativesTRIM37-amplification

Substanzen

Protein Serine-Threonine KinasesQuinazolinesPLK4 protein, humanUbiquitin-Protein LigasesAntineoplastic AgentsProtein Kinase InhibitorsTripartite Motif ProteinsTRIM37 protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang110016, PR China.
  • 3D BioOptima, 1338 Wuzhong Avenue, Suzhou215104, China.
  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California94305, United States.

ORCID-Profile: Dongmei Zhao

Förderung

  • 3D BioOptima (Suzhou)
  • Program for Innovative Research Team of the Ministry of Education
  • Program for Liaoning Innovative Research Team in University

Zitieren

APA

Liu, N., Qi, Z., Sun, W., Tong, M., Shi, X., Wang, H., Mu, S., Hu, N., Luo, Z., Fan, C., Zhang, H., Gao, Z., Sun, Y., Zhao, D., & Cheng, M. (2026). Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma. Journal of Medicinal Chemistry, 69(15), 19065-19087. https://doi.org/10.1021/acs.jmedchem.6c01348

Vancouver

Liu N, Qi Z, Sun W, Tong M, Shi X, Wang H, et al. Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma. Journal of Medicinal Chemistry. 2026;69(15):19065-19087. doi:10.1021/acs.jmedchem.6c01348

BibTeX
@article{Liu2026,
  author = {Liu, Nian and Qi, Zehui and Sun, Wenqiang and Tong, Minghui and Shi, Xuan and Wang, Han and Mu, Shuyi and Hu, Ningyuan and Luo, Zirui and Fan, Cunzheng and Zhang, Haoyu and Gao, Zixuan and Sun, Yin and Zhao, Dongmei and Cheng, Maosheng},
  title = {Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {19065--19087},
  doi = {10.1021/acs.jmedchem.6c01348}
}
Kostenlos starten →